Hodgkin Lymphoma Archives - Oncology Nurse Advisor

Researchers analyzed long-term follow-up data from 2 clinical trials.

Low-Dose Anti-PD1 Therapies in Relapsed/Refractory Classical Hodgkin Lymphoma

By

Vicki Moore, PhD

September 9, 2020

A small study suggests that low-dose pembrolizumab or nivolumab may be effective and safe for the treatment of r/r classical Hodgkin lymphoma.

There are currently limited data to inform an optimal treatment strategy for CRS.

Lymphoma

Two Trials Evaluate CAR-T Cell Therapy for Relapsed/Refractory Hodgkin Lymphoma

By

Vicki Moore, PhD

August 11, 2020

CD30 CAR-T cell treatment after lymphodepletion may produce antitumor activity without significant toxicity in relapsed or refractory Hodgkin lymphoma.

Lymphoma

Pembrolizumab Superior to Brentuximab Vedotin for Treatment of Relapsed/Refractory Classical Hodgkin Lymphoma

By

Lauren Dembeck, PhD

June 3, 2020

Pembrolizumab showed statistically significant improvement in PFS compared with brentuximab vedotin in patients with r/r cHL.

A doctor and patient discuss medical files.

Lymphoma

Nivolumab Plus AVD Found Highly Effective in Early-Stage Unfavorable cHL

By

Andrea S. Blevins Primeau, PhD, MBA

May 14, 2020

First-line treatment of early-stage, unfavorable classic Hodgkin lymphoma with nivolumab plus doxorubicin, vinblastine, and dacarbazine resulted in high response rates and PFS in a phase 2 study.

Lymphoma

Brentuximab Vedotin With Bendamustine for Patients With Refractory or Multiple Relapsed Classic Hodgkin Lymphoma

By

Vicki Moore, PhD

March 30, 2020

A retrospective analysis found encouraging evidence for the use of BvB in treatment of RR-cHL.

Lymphoma

Comparing Cost-Effectiveness of First-Line Treatment Approaches for Hodgkin Lymphoma

By

John Schieszer, MA

February 25, 2020

Of 5 treatment regimens assessed, a PET-adapted de-escalation treatment approach was found to be the most cost-effective in 87% of cases modelled.

Blood and Lymphatic Cancer: Targets and Therapy

Publishers Alliance

The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma

January 3, 2020

[Blood and Lymphatic Cancer: Targets and Therapy] First approved in 2011, the CD30 directed antibody-drug conjugate brentuximab vedotin is used in previously untreated and R/R classical Hodgkin lymphoma (cHL). In this review, researchers discuss the expanded indications for BV in cHL to include maintenance therapy after ASCT and in combination with chemotherapy and immunotherapy.